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Abstract
Background: Telomerase activation, a critical step in cell immortalization and oncogenesis, is partly regulated by
alternative splicing. In this study, we aimed to use the Marek’s disease virus (MDV) T-cell lymphoma model to
evaluate TERT regulation by splicing during lymphomagenesis in vivo, from the start point to tumor establishment.
Results: We first screened cDNA libraries from the chicken MDV lymphoma-derived MSB-1 T- cell line, which we
compared with B (DT40) and hepatocyte (LMH) cell lines. The chTERT splicing pattern was cell line-specific, despite
similar high levels of telomerase activity. We identified 27 alternative transcripts of chicken TERT (chTERT). Five were
in-frame alternative transcripts without in vitro telomerase activity in the presence of viral or chicken telomerase
RNA (vTR or chTR), unlike the full-length transcript. Nineteen of the 22 transcripts with a premature termination
codon (PTC) harbored a PTC more than 50 nucleotides upstream from the 3’ splice junction, and were therefore
predicted targets for nonsense-mediated decay (NMD). The major PTC-containing alternatively spliced form
identified in MSB1 (ie10) was targeted to the NMD pathway, as demonstrated by UPF1 silencing. We then studied
three splicing events separately, and the balance between in-frame alternative splice variants (d5f and d10f) plus
the NMD target i10ec and constitutively spliced chTERT transcripts during lymphomagenesis induced by MDV
indicated that basal telomerase activity in normal T cells was associated with a high proportion of in-frame non
functional isoforms and a low proportion of constitutively spliced chTERT. Telomerase upregulation depended on
an increase in active constitutively spliced chTERT levels and coincided with a switch in alternative splicing from an
in-frame variant to NMD-targeted variants.
Conclusions: TERT regulation by splicing plays a key role in telomerase upregulation during lymphomagenesis,
through the sophisticated control of constitutive and alternative splicing. Using the MDV T-cell lymphoma model,
we identified a chTERT splice variant as a new NMD target.
Background
The telomeric enzyme complex, consisting of a telomer-
ase reverse transcriptase (TERT) and an RNA template
(TR), adds terminal telomeric repeats to the end of the
chromosome, to maintain telomere length during cell
proliferation [1,2]. Most normal somatic cells lack telo-
merase activity, whereas telomerase activation is
observed in proliferating cells and cancer cells [3,4].
Telomerase activity is highly regulated in lymphocytes,
being expressed only in activated lymphocytes [5]. In
humans, the hTR transcript is constitutively produced,
whereas the production of hTERT is highly regulated at
both the transcriptional and post-transcriptional levels
[6,7]. Alternative splicing of the hTERT transcript plays
a role in this regulation and 10 alternatively spliced sites
have been identified in the hTERT gene [8]. Notably,
the alpha isoform, corresponding to an in-frame deletion
in the RT motif, appears to be a dominant inhibitor of
telomerase activity [9,10].
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cing is an important gene regulation mechanism, help-
ing to increase the diversity of proteins by favoring the
production of large numbers of isoforms with dominant
positive or negative functions [11]. However, almost one
third of all alternative transcripts harbor a premature
termination codon (PTC) and most are thought to be
degraded by the nonsense-mediated mRNA decay
(NMD) pathway [12].
NMD occurs in all eukaryotic cells. This cell surveil-
lance system detects and rapidly degrades aberrant
mRNAs containing PTCs (for reviews, see [13,14]). Ter-
mination codons are generally considered premature if
they occur more than 50 to 55 nucleotides upstream
from a final splice site recognized by the exon junction
complex (EJC). The EJC serves as a platform for the
binding of UPF factors, which are considered to be the
conserved core of the NMD machinery. UPF1 is an
ATP-dependent RNA helicase and RNA-dependent
ATPase activated by phosphorylation. It is a crucial ele-
ment of the NMD machinery, because silencing of the
upf1 gene results in the stabilization of PTC-containing
mRNAs in all organisms in which NMD has been inves-
tigated. This surveillance mechanism not only eliminates
abnormal transcripts, but also controls transcript levels
through a global system known as RUST (regulated
unproductive splicing and translation) [15,16]. Several
recent studies have demonstrated that the role of alter-
native splicing in gene regulation has been largely
underestimated and have shown that this process is
involved in homeostatic regulation, pathogenesis [17]
and, particularly, in cancers [18,19].
Gallid herpesvirus 2 (GaHV-2), also known as Marek’s
Disease Virus (MDV), is an avian oncogenic alphaher-
pesvirus that induces T-cell lymphomas in chickens.
These tumors develop within six weeks of infection in
birds, making this model a unique asset for studies of
the kinetics of disease induction and progression in a
natural host system. This model has already proved
valuable for studies of human lymphoma [20]. Indeed,
Marek’s disease is the only naturally occurring model
for human lymphomas involving the overexpression of
CD30 [21]. GaHV-2 is also the only virus harboring a
viral homolog of the telomerase RNA template (vTR),
with a sequence 88% identical to that of the chicken tel-
omerase RNA (chTR). Functional analysis has shown
that vTR can reconstitute telomerase activity by inter-
acting with chicken TERT (chTERT) more efficiently
than chTR [22]. Furthermore, vTR expression increases
during GaHV-2 lymphomagenesis and this increase is
correlated with the upregulation of telomerase activity,
which is not associated with an upregulation of chTERT
transcription [23,24]. Telomerase is also activated by a
number of human oncogenic viruses [25], but
investigations in this case are obviously restricted to
in vitro analyses of cell lines derived from tumors or
transformed in vitro. The chicken telomerase has a
number of key features in common with the human
enzyme, in terms of the organization of the TERT and
TR genes and the regulation of telomerase activity [26].
Furthermore, as for hTERT, many alternative variants of
chTERT have been identified and are thought to play a
role in the regulation of telomerase activity [26,27]
In this study, we investigated the alternative splicing of
chTERT in the MDV lymphomagenesis model. We
report the identification of 27 alternative transcripts of
chicken TERT cloned during a comparison of three dif-
ferent chicken cell lines including MSB-1, a MDV
tumor cell line. Five alternative transcripts were in-
frame transcripts, whereas the other 22 were found to
harbor a PTC. We then demonstrated that the in-frame
transcripts generated proteins with no telomerase activ-
ity in vitro, whereas telomerase activity was detected for
the products of constitutively spliced transcripts. The
major PTC-containing variant found in the MDV cell
line was shown to be a target of NMD in an upf1 silen-
cing test. Finally, investigation of the splicing-mediated
regulation of chTERT in vivo,i nM D V - i n f e c t e dc h i c k -
ens, demonstrated that basal telomerase activity in nor-
mal T cells was associated with a high ratio of in-frame
non-functional isoforms to functional constitutively
spliced chTERT. During the upregulation of telomerase
associated with lymphomagenesis, an increase in active
constitutively spliced chTERT transcript levels was
observed that coincided with a switch in alternative spli-
cing from the in-frame type to the NMD type. These
results suggest that the regulation of telomerase activity
is partly dependent on the fine regulation of splicing of
chTERT, regulating the abundance of functional
chTERT mRNA.
Results
Complex profile of chTERT alternative transcripts
We first compared the pattern of alternative chTERT
transcript production from the MDV T- MSB-1 cell line
with that of two other cell lines: the DT40 B cell line,
and the epithelial LMH cell line. Three cDNA libraries
encompassing the T and RTr e g i o n so fc h T E R Tw e r e
generated (Figure 1).
The ratio of constitutively to alternatively spliced
TERT transcripts was the first major difference identi-
fied between cell lines. Constitutively spliced transcripts
accounted for about half of all transcripts in both lym-
phoid cell lines (52.4% and 47.6% for MSB1 and DT40,
respectively), but only 24.4% of transcripts in the LMH
cell line. However, no significant differences in telomer-
ase activity were observed between the three cell lines
(telomerase activity of 152272 for MSB1, 165818 for
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clear correlation between this ratio and telomerase
activity. In addition to constitutively spliced chTERT,
we identified 27 alternative transcripts generated
through the five typical splicing events: exon skipping,
inclusion of a new exon cassette, cases of intron reten-
tion, use of alternative splice donor sites and use of
alternative splice acceptor sites. Most of the alternative
transcripts were generated by one of the four frequent
splicing events: i7ec, i10ec, d5f and d8f. Each cell line
displayed a number of rare specific transcripts generated
by a specific combination of the four major events or a
combination of one or more of these events with a rare
splicing event (Figure 1).
The LMH cell line displayed a preferential deletion of
exons, (Figure 1). By contrast, lymphoid cell lines were
characterized by the insertion of introns generated by exo-
nization (inclusion of intronic sequences in constitutive
transcripts), through the formation of exon cassettes or
the retention of all or part of an intron (Figure 1). Never-
theless, we observed differences in the distribution of spli-
cing events between MSB1 T cells and DT40 B cells. For
instance, major differences were seen for one of the major
splicing events, i10ec (alone or in association with other
splicing events), which was more frequently detected in
MSB-1 than in DT40 cells (28.3% versus 8.2%).
Most of the detected alternative transcripts (22/27)
harbored premature termination codons (PTCs) (Figure
Figure 1 Alternative transcripts of chTERT identified in three avian cell line. At the top, we show a schematic diagram of telomerase
protein, showing major conserved protein motifs, including reverse transcriptase domains 1 and 2 and the A, B, C, D and E motifs, and of the
chTERT gene, with its 16 exons shown as gray boxes. The PCR primers are shown as arrows below the diagram. Each alternative transcript is
shown on the right, with the splicing event depicted as a clear gray box for insertion of the exon cassette; dark lines indicate deletion, black
boxes indicate intron retention and white boxes indicate the deletion of part of an exon. Positions of premature stop codons (PTCs) are
indicated by black triangles. On the left, we show the name of the spliced transcripts, the presence or absence of a PTC with its position relative
to the 3’ exon-exon junction and represented as a function of cell line. The name of the transcript is indicated on the left and is coded as
follow: iXec for insertion of exon cassette X, dXf for full deletion of exon X, dXp for partial deletion of exon X, iXp for retention of part of intron
X and iXf for insertion of full intron X.
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located more than 50 nucleotides upstream from the 3’
splice junction and were predicted to result in NMD-
sensitive transcripts. Of the five remaining transcripts
encoding in-frame isoforms of chTERT, only the i7ec
transcript, corresponding to an inclusion of 12 amino
acids (aa) between regions A and B of the protein, pre-
served the catalytic site of TERT, the four remaining
transcripts involving the deletion of exon 5 (d5f), result-
ing in the deletion of amino acids from motifs 2 and A
(Figure 1 and 2).
None of the in-frame isoforms of chTERT is functional
We assessed the telomerase activity of three reconsti-
tuted in-frame isoforms (Figure 2). Isoforms i7ec and
d5f were identified as alternative transcripts (Figure 1)
and isoform d10f was reconstructed for individual test-
ing of the effect of the d10f splicing event, on which we
subsequently focused specifically. We inserted the
cDNAs of the isoforms downstream from the T7
promoter, for the assessment of telomerase activity in
an in vitro assay [28]. Telomerase activity was measured
i nt h ep r e s e n c eo fin vitro transcribed vTR or chTR.
Consistent with published results [28], the full-length
chTERT transcript reconstituted an efficient telomerase
complex with both TRs with vTR that was 58% more
efficient than chTR, whereas none of the in-frame
spliced isoforms reconstituted telomerase activity. Thus,
i7ec, despite the preservation of its RT motifs, displayed
no telomerase activity and, as expected, in-frame iso-
forms with deletions in the RT domains were not able
to reconstitute telomerase activity. As exon 5 (d5f) was
deleted from all the four remaining in-frame isoforms
other than i7ec, (Figure 1), we can conclude that all the
in-frame isoforms are inactive. We then assessed the
dominant negative function of these isoforms on telo-
merase activity when produced together with the active
full-length chTERT (Figure 2C). All the isoforms acted
as negative regulators, with inhibition levels of 74% for
d5f to 58% for d10f when compared with the exclusive
Figure 2 chTERT in-frame isoforms are non functional in the in vitro telomerase assay. (A) Schematic diagram of the 3 reconstituted in-
frame isoforms of chTERT inserted into pcDNA under the control of the T7 promoter. Amino acids deleted or inserted in each isoform are
indicated and those belonging to the RT motif are underlined. Plasmids were used to produce recombinant in vitro-translated proteins that were
incubated in the presence of in vitro-transcribed vTR or chTERT before the TRAP assay. (B) The histogram shows telomerase activity relative to
the value obtained with vTR in the presence of the full-length constitutively spliced chTERT transcript arbitrary set at 100%. (C) Histograms show
telomerase activities for a mixture (1:1) of in vitro-translated full-length chTERT and the indicated isoform in the presence of vTR or chTR. The
values obtained with the mixture of full-length chTERT and isoform are expressed relative to the value for the full-length chTERT, arbitrarily set at
100%. The histogram shows the mean and standard deviation obtained from 3 biological analyses.
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cant difference was seen between chTR and vTR,
demonstrating that the inhibition mechanism did not
depend on the nucleotide differences identified between
vTR and chTR [28]. Thus, all the chTERT isoforms
tested seemed to have dominant negative effects on telo-
merase activity, whether with chTR or vTR.
The i10ec variant undergoes NMD
The i10ec transcript was the most frequently repre-
sented transcript with predicted sensitivity to NMD in
the MSB1 cell line. We therefore followed this transcript
during lymphomagenesis. We evaluated its sensitivity to
N M Db yb l o c k i n gt h eN M Dp a t h w a y ,u s i n gs i R N At o
target UPF1, the major NMD factor in the transfected
LMH cell line. We chose to study LMH cells for techni-
cal reasons, essentially linked to transfection efficiency.
Indeed MSB1 (or DT40) cells are lymphocytes and are
difficult to transfect (2 to 5% transfection efficiency
associated with high mortality rates of 70-90%). As i10ec
was not detected in chTERT alternative transcripts of
LMH (Figure 1), we first determined whether transcripts
harboring the i10ec splice event and thus defined as var-
iant i10ec were detectable by PCR on LMH cDNA fol-
lowed by fragment capillary electrophoresis analysis
assays (CEAA) (see additional file 1: comparison of
cDNA library and fragment analysis). This more sensi-
tive technique, focusing on the specific amplification, by
PCR, of short fragments, led to detection of the i10ec
v a r i a n ta taf r e q u e n c yo f1t o5 %w i t hr e s p e c tt of u l l -
length chTERT, thus rendering silencing experiments
feasible. We observed significant increases in relative
i10ec levels of 1.6 and 1.7 when the NMD pathway was
inhibited with 25 and 50 pmol of siRNA against UPF1,
respectively, as shown by comparisons with a non-
silenced sample used as a control and normalized to 1
(Figure 3A). The effective targeting of UPF1 by siRNA
was also confirmed by monitoring UPF1 mRNA levels.
UPF1 was strongly downregulated by 25 and 50 pmol of
siRNA UPF1 (71 and 81%, respectively) (Figure 3B).
These results demonstrate that the i10ec variant was
efficiently detected and degraded by NMD.
The increase in telomerase activity during the
lymphomagenesis induced by MDV is related to the
upregulation of constitutively spliced chTERT at the
expense of alternatively spliced in-frame isoforms
Finally, we investigated the contribution of chTERT
alternative splicing to the regulation of telomerase activ-
ity during the course of the lymphomagenesis induced
by MDV. As it is difficult to amplify cDNA from the
relatively long chTERT mRNA fragment present at low
abundance in PBLs, we developed two independent frag-
ment capillary electrophoresis analysis assays for investi-
gating the dynamics of chTERT splicing regulation in
vivo. In our assay, we chose to monitor changes in the
ratio of the constitutively spliced transcript to variants
resulting from two major splicing events, d5f and i10ec,
identified in the MSB1 cell line, currently used as the
reference cell line in investigations of Marek’sd i s e a s e
Figure 3 Downregulation of the i10ce variant by NMD. (A) Upf1 depletion increases levels of the chTERT splice variant i10ce. Levels of i10ce
are expressed relative to total chTERT levels. Peak areas of i10ec were obtained by capillary electrophoresis analysis of the PCR products
targeting exon 10, generated from cDNA from 1 well of P6 transfected with 25 pmol or 50 pmol of siUPF-1. The histogram shows the mean and
standard deviation obtained from 4 biological analyses. All values are expressed as a fold difference with respect to “no silencing” (NS), for which
the value was fixed at 1. (B) siUpf1 knockdown of Upf1. The histogram shows Upf1 mRNA levels, calculated by RT-PCR analysis. Upf1 levels in
each sample were normalized with respect to GAPDH levels for the corresponding sample. The values obtained for “no silencing” (NS) LMH cells
were set at 100%.
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lymphoma cells in vivo. Variant d5f encodes a non-func-
tional isoform of chTERT and i10ec, generating a var-
iant targeted by the NMD pathway. Furthermore, the
assay detecting the i10ec variant also detected the d10f
variant, which would also be expected to generate a
non-functional isoform, as demonstrated by the in vitro
telomerase assay (Figure 2). Our assays were first opti-
mized with the CD4+-sorted MSB1 cell line. The results
obtained in fragment capillary electrophoresis analysis
assays of cDNA samples were similar to those obtained
for library analysis, although the ratios differed very
slightly (see additional file 1: comparison of cDNA
library and fragment analysis). These results confirm
that fragment analysis is an appropriate technique for
studying spliced chTERT and is suitable for use with
sorted chicken CD4
+ T cells.
We first measured telomerase activity at five previously
identified crucial time points (d0, d7, d14, d22 and d28)
[24](Figure 4). The results obtained with CD4
+ Tc e l l s
were similar to those obtained with PBL: (i) basal
telomerase activity was detected in CD4
+ T cells from
non infected chickens (67527), (ii) a slight induction of
telomerase activity was first observed at 7 days (71750),
corresponding to the phase of primary semi-productive
infection (iii), this induction peaked at 14 days p.i.
(107800), corresponding to the expected time of lym-
phoma onset and (iv) persisted until 28 days p.i.
(135310). Capillary electrophoresis analysis of splicing
variants 5 and 10 was then performed on cDNA
extracted from the same CD4
+ T-cell samples. Variants 5
and 10 had three major features in common: i) almost all
the chTERT transcripts detected in CD4+ T cells from
non infected chickens in tests for variants 5 and 10 were
alternatively spliced (99.8% and 99.3% respectively), ii) in
detection tests for both these variants, constitutively
spliced transcripts became detectable from day 7 p.i., and
their detection coincided with the increase in telomerase
activity, iii) constitutively spliced transcript levels
increased throughout infection (Figure 4).
However, the changes in splicing pattern differed
between variants 5 and 10. For the d5f variant, we
Figure 4 Regulation of chTERT splicing involving variants 5 and 10 during lymphomagenesis in vivo. Proportions of constitutively spliced
chTERT transcript (in blue) and alternatively spliced variants d10f+i10ec (in yellow) and the d5f variant (in green), as shown in the panels on the
right and left, respectively. The proportions correspond to the peak area obtained by capillary electrophoresis analysis of PCR targeting exon 5
(A) or 10 (B), performed on cDNA extracted from sorted CD4
+ T cells sampled from GaHV-2-infected chickens at 5 different time points after
infection, as indicated on the x-axis. The curve shows telomerase activity, which was obtained by summing the peak areas corresponding to the
elongation products (right y-axis) (C) Proportions of d10f (green) and i10ec (orange) variants, as indicated above the graph and corresponding to
100% of alternative splice variants10 at each time point after infection, as shown in (B).
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tively spliced transcripts from day 7 (2.3%), peaking at
d22 (63.9%) (Figure 4A). By contrast, with variant 10
(encompassing both d10f and i10ec), the levels of consti-
tutively spliced transcript increased considerably
between d0 and d7 (from 0.7% to 66.4%) and remained
high until day 28 (92.4%) (Figure 4B). Investigation of
the ratio of d10f to i10ec showed a clear shift from d10f
to i10ec at d7 (Figure 4C). Thus, at d0, the d10f variant,
was, with d5f, almost the only alternatively spliced var-
iant detectable. Then, beginning on d7, the proportion
of the i10ec variant, which was predicted to be sensitive
to NMD, increased strongly (>60%). These results indi-
cate that (i) variants encoding in-frame non functional
isoforms (d5f and d10f) predominate in uninfected CD4
+ T cells and are associated with basal levels of telomer-
ase activity (ii) the activation of telomerase is accompa-
nied by an increase in the proportion of constitutively
spliced transcripts and a decrease in the proportion of
in-frame alternatively spliced transcripts, favoring the
predicted NMD-sensitive transcript.
Discussion
The regulation of telomerase activity is a complex pro-
cess involving several steps operating at both the tran-
scriptional and post-transcriptional levels. In recent
years, TERT splicing has been extensively studied in
many types of human cells, tissues and tumors and in
other organisms, such as plants, nematodes and ciliates
[29]. A number of different alternative transcripts have
been described, but little is known about the cause of
splicing variant production and the ways in which spli-
cing variant levels are regulated [29]. This is particularly
true for the regulation of splicing during the cell trans-
formation process and the dynamics of this process in
vivo. In this study, we carried out RT-PCR fragment
analysis to study the dynamics of the ratio of the consti-
tutively spliced productive form of chTERT to three
alternatively spliced non productive forms – one NMD-
sensitive transcript and two in-frame transcripts – in
chicken CD4
+ T cells, during a lymphomagenic process
induced by MDV, an oncogenic herpes virus, in its nat-
ural host. In our model, lymphoma was observed on day
28 p.i. in 100% of infected chickens, facilitating analyses
of the dynamics of gene regulation during oncogenesis
in vivo [24]. Another major and unique advantage of
our model is that we were able to control the start of
tumorigenesis through the inoculation of chickens with
t h ev i r u s .U s i n gt h i sa p p r o a c h ,w eh a v ep r e v i o u s l y
shown that telomerase activation begins seven days after
infection and peaks 22 days after infection, this time
point being correlated with the first detection of the
tumor in animals. Furthermore, telomerase activation
and lymphomagenesis were correlated with upregulation
of the vTR transcript, but no upregulation of the chTR
and chTERT transcripts was seen [23,24]. In this study,
we investigated telomerase regulation in more detail, by
following the regulation of chTERT splicing in this
model. Constitutively spliced transcript was almost
undetectable at d0 in CD4
+ T lymphocytes, but its levels
gradually increased, peaking 22 days after infection, on
the day of lymphoma onset. These data are the first to
be obtained in vivo and are consistent with previous in
vitro observations after the v-Rel transformation of
spleen cells from chickens [27]. Moreover, the regula-
tion of telomerase activity in human T lymphocytes
seems to be similar, as full-length hTERT is undetect-
able in normal T cells and an increase in telomerase
activity in activated T cells is associated with the induc-
tion of full-length hTERT mRNA production [30]. We
also confirmed the results obtained for in vitro analyses
of human tissues, with telomerase activation involving
the induction, or a switch to production of the full-
length hTERT mRNA, as shown in various tissues
[31-34].
Studies on spliced hTERT transcripts have generally
focused on two major isoforms of hTERT: alpha (in-
frame isoform with a 36 bp deletion in motif A) and
beta (isoform introducing a PTC in exon 10) [35]. The
in-frame alpha isoform of hTERT has been shown to
regulate telomerase activity negatively, acting as a domi-
nant negative inhibitor [9,10]. We identified five in-
frame isoforms of chTERT, all of which had modifica-
tions affecting the RT motifs of telomerase. We have
shown that three reconstituted in-frame isoforms, i7ec,
d5f and d10f, are inactive, being unable to reconstitute
telomerase activity in vitro with either vTR or chTR.
These isoforms also seem to act as negative regulators,
as the association of the full-length chTERT transcript
with an in-frame isoform decreased telomerase activity
b yaf a c t o ro f2t o2 . 5i nt h ein vitro telomerase assay
(Figure 2C). We can therefore hypothesize that the low
basal levels of telomerase activity in normal T lympho-
cytes are controlled by in-frame non-functional iso-
forms, as these are almost the only isoforms detected
(>99%). The basal telomerase activity observed at d0
(Figure 4) was associated with very low levels of consti-
tutively spliced active chTERT transcripts (0.5%), consis-
tent with a previous study [36] demonstrating that
telomerase-positive cell lines contain only a few mole-
cules of functional hTERT mRNA.
We also observed that telomerase activation associated
with an increase in constitutively spliced transcript
l e v e l sw a sa c c o m p a n i e db yas w i t c hi nt h ep r o f i l eo f
alternative transcripts from in-frame transcripts encod-
ing non functional isoforms to NMD-sensitive tran-
scripts. The ratio of the NMD-sensitive i10ec to the in-
frame d10f increased markedly with the upregulation of
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PTC of i10ec was located 74 nucleotides upstream from
the last exon-exon junction, consistent with the defini-
tion of PTCs targeted by the NMD pathway. Neverthe-
less, the NMD sensitivity of the PTC-containing i10ec
transcript was definitively confirmed by UPF1 silencing,
which increased i10ec levels by a factor of up to 1.7
(Figure 3), consistent with previous reports of a increase
in mRNA levels by a factor of 1.8 for PTC-containing
COL alpha-2 [37] or H-ras [38]. The chTERT i10ec
splice variant was thus identified as a new NMD target.
These results confirm the hypothesis put forward by
Chang H and Delany M. E. (2006) in a study identifying
19 chTERT spliced variants in different cell types, 16 of
which (including i10ec) were predicted to have a PTC
leading to degradation by the NMD pathway.
The change in the ratio of d10f to i10ec strongly sug-
gests that differential splicing in favor of the NMD-sen-
sitive transcript may be regulated by splicing activators
or repressors, leading to the overrepresentation of con-
stitutively spliced transcripts with respect to in-frame
negative regulator isoforms. Recent studies have indi-
cated that NMD is a sophisticated tool in physiological
autoregulatory gene expression [12]. Lewis et al. [15]
suggested that the coupling of splicing and NMD results
in RUST, the mechanism regulating the ratio of produc-
tive and unproductive spliced forms of many genes, as
demonstrated for the splicing factor SC35 [39]. Figure 5
schematically represents a model accounting for our
observations. In lymphocytes, in which the ratio of con-
stitutively spliced and in-frame negative regulator iso-
forms of TERT must be tightly controlled to maintain
basal telomerase activity, the ratio of NMD-sensitive
transcripts may be a major sensor (Figure 5). Moreover,
with telomerase upregulation, the switch to NMD-sensi-
tive transcripts may contribute to downregulation of the
in-frame isoform acting as a negative regulator (Figure
5). Global regulation of this type, involving both an in-
frame isoform and an NMD-sensitive transcript, has
been described for serum response factor (SRF) [40]. In
this system, the abundance of SRF is reduced by RUST,
but SRF gene expression is also regulated by an in-
frame isoform of SRF repressing transcription of the
SRF gene itself. In our model, this feedback mechanism
not only makes use of the active transcript ratio, but is
also based on the negative regulator ratio. Interestingly,
this model has also been proposed for regulation of the
abundance of SR protein [41].
Conclusion
Our findings strongly suggest that the regulation of
TERT splicing plays a key role in the upregulation of
telomerase activity in vivo, by controlling the proportion
of active constitutively spliced transcripts with an in-
Figure 5 Model of the splicing regulation of chTERT during lymphomagenesis.
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sensitive transcript. Regulation of the ratio of NMD-sen-
sitive transcript to in-frame transcript encoding the
negative regulator isoform also plays a key role in sup-
pressing telomerase activity in normal cells, in which
negative regulator isoforms predominate, whereas
NMD-sensitive transcripts become predominant when
telomerase is upregulated during oncogenesis.
Methods
Cell line culture and experimental assay in vivo
Three avian cell lines were used: GaHV-2 lymphoma-
derived MSB-1 T cells [42] currently used as the refer-
ence cell line in Marek’s disease investigation, the B-cell
line DT40 [43] and the LMH hepatocellular carcinoma
cell line [44]. Six-week-old White Leghorn specified
pathogen-free susceptible B13B13 chickens were
infected with GaHV-2 RB-1B virus [45]. Blood was
obtained from two birds at 7, 14 and 22 days post-infec-
tion (dpi) and from one bird at 28 dpi, as the other bird
had already died. The first time point (0 dpi), corre-
sponded to the pooling of 2 ml blood samples from
each of the chickens, taken before infection. All experi-
mental procedures were conducted in accordance with
approved protocols for the use of animals in research.
Transient transfection with siRNA
Transient transfection with siRNA was carried out in
six-well plates. LMH cells were transfected with 25 or
50 pmol of siRNA per well, in the presence of Lipofecta-
mine 2000 reagent (Invitrogen), according to the manu-
facturer’s protocol. Cells were harvested 48 hours later
for RT-PCR analysis of UPF1, GAPDH and chTERT
splicing variant i10ec. The siRNA targeting UPF1
(siUPF1) [GGUGGAAGAUGUAAUUAUU] was
designed and purchased from Eurogentec.
Flow cytometry analysis and cell sorting
Peripheral blood lymphocytes (PBL) were isolated from
blood [46] and immunolabeled for the sorting of CD4
+
T cells. The CD4 antigen was detected by incubation
with the monoclonal antibody (Ab) CD4-UNLB, 8210-
01 (Southern Biotechnology), followed by goat anti-
mouse Ig conjugated to R-phycoerythrin (PE) (Jackson
Immunoresearch). The cells were then analyzed by flow
cytometry and PE-labeled cells were sorted and recov-
ered for RNA and protein extraction, with a MoFlo™
apparatus (Beckmann Coulter, Fort Collins, USA) and a
high-speed cell sorter. The sorting speed was around
35,000 cells per second.
RNA extraction, cDNA synthesis and PCR amplification
Total RNA was extracted from 2 × 10
6 cells, with the
RNAble Kit (Eurobio). The cDNA was synthesized with
SuperScript III reverse transcriptase (Invitrogen), using
oligo (dT) priming (Eurogentec), according to the man-
ufacturer’s instructions. The RT region of the chTERT
gene, and gapdh and upf1 genes were amplified by PCR
in Ready Master Mix 1.1X (Abgene), using three pairs
of primers: TERT-e3 with TERT-e16 (Table 1, Figure
1A), GAPDHs (GTCCTCTCTGGCAAAGTCCAAG)
with GAPDHr (CCACAACATACTCAGCACCTGC)
designed from the Gallus gallus gapdh sequence (NCBI
genebank number M11213.1) and UPF1s (GGGCT
CCGAGTTCGAGTTCA) with UPF1r (CAGAATGC-
CATCCGGTCCAT) from the predicted sequence of the
Gallus gallus upf1 gene (NCBI reference sequence
NC_006115.2). The PCR products for UPF1 and
GAPDH were analyzed by agarose gel electrophoresis.
Adobe Photoshop 7.0 software (Adobe Systems, USA)
was used to calculate the signal intensities for UPF1
relative to the GAPDH loading control.
Generation and screening of cell-line cDNA libraries
PCR products corresponding to the chTERT RT region
were inserted into the pGEM-T Easy vector (Promega)
and positive clones were randomly selected after screen-
i n gf o rt h ep r e s e n c eo ft h ei n s e r tb yP C R .I n d i v i d u a l
selected clones were then screened for the type of alter-
native transcript, by running PCR with a panel of primer
pairs (Table 1) covering each of the exons (4 to 15) of
the chTERT cDNA. For the validation of exon PCR
screening, 13 representative clones were also completely
sequenced (MWG Biotech). Sequences were analyzed
with DNASTAR sequence analysis software (Lasergene).
PCR fragment analysis of chTERT splicing variants 5 and
10
The ratios of constitutively to alternatively spliced tran-
scripts from cell lines and sorted CD4
+ Tc e l l sw e r e
determined by fluorescent fragment analysis [23,24].
Nested-PCR was performed on the first PCR amplifica-
tion product of the chTERT RT region, in Ready Master
Mix 1.1X (Abgene), with specific tetrachlorofluorescein
phosphoramidite-labeled forward primers and unlabeled
reverse primers specific for exon 5 or 10 (Table 1).
Amplification products were analyzed with an auto-
mated ABI Prism 310 fragment analyzer (Perkin Elmer
Life Sciences) and the ratio of spliced transcripts was
determined as a percentage of the peak area for consti-
tutively (C) versus alternatively (A) spliced transcripts.
Each assay was performed at least three times.
Reconstitution in vitro of the telomerase complex
The three cDNAs for alternative transcripts of chTERT
– d5f, d10f, and i10ec – were inserted into pcDNA 3
and the telomerase complex was reconstituted [28]. We
incubated 1 μg of vTR or chTR RNA transcribed in
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spliced and full-length chTERT transcripts expressed in
the TNT system (Promega). We assessed the inhibition
of telomerase activity by the isoforms with 2 μlo ft h ein
vitro-translated full-length isoform and 2 μlo fin vitro-
translated isoform. Aliquots of ribonucleoprotein assem-
bly products were used for the assessment of telomerase
activity in the telomere repeat amplification protocol
(TRAP) assay [28].
Telomere repeat amplification protocol (TRAP) assay
The telomerase activity of sorted CD4
+ T cells from
chicken in in vivo infection assays and of in vitro
reconstituted complexes was quantified as previously
described [28,24]. Briefly, telomerase activity was
quantified with 500 ng of protein extracted from CD4
+Tc e l l s[ 2 4 ]o r0 . 3μlo fin vitro ribonucleoprotein
assembly products [28]. PCR was carried out with the
6-carboxytetramethylrhodamine-labeled forward pri-
mer TS (5’-AATCCGTGCAGCAGAGTT-3’)a n dC X -
ext (5’-CCCTAACCCTAACCCTAACCCTAA-3’)a s
the reverse primer. An internal amplification standard
(ITAS) was added to the PCR mixture in quantitative
TRAP assays or was used independently as a PCR
control. PCR products were analyzed by capillary elec-
trophoresis (ABI Prism 310; PerKinElmer Life
Sciences). The telomerase activity of each protein
extract was estimated by adding together the inte-
grated values for each telomerase elongation product
of at least 60 bp.
Table 1 Primers used in the study
Oligonucleotide
1 Localization
2 Sequence
3 Screening
tert e3-M331s e3 (2210-39) CTGTTCCTGCCTATGAACATTGTTACCGTG chTERT cDNA
tert e3M137-s e3 (2260-80) CTATACTGGCTGATGGATTCC exon 4
M139s e4 (2480-500) CATCAAGGCTCCGGTTCATTC exon 5
M141s e5 (2680-700) GGGAGAGATGATATCTACAGG exon 6
M142r e5 (2700-680) CCTGTAGATATCATCTCTCCC exon 4
M143s e6 (2815-35) GTGGAAGTGATATCACAGGTC exon 7
M144r e6 (2835-15) GACCTGTGATATCACTTCCAC exon 5
M145s e7 (2974-92) GTGTCCAAGCTTCAAGAGA exon 8
M146r e7 (2992-74) TCTCTTGAAGCTTGGACAC exon 6
M147s e8 (3040-60) AATGAGAACAGTTCCACCCTG exon 9
M148r e8 (3060-40) CAGGGTGGAACTGTTCTCATT exon 7
M149s e9 (3172-92) AGCTTATGCTACGGAGACATG exon 10
M150r e9 (3192-72) CATGTCTCCGTAGCATAAGCT exon 8
M151s e10 (3258-79) GCTGGTTACGCCACATTTAATG exon 11
M152r e10 (3279-58) CATTAAATGTGGCGTAACCAGC exon 9
M153s e11 (3373-93) GATGATATCCCGGGATGTTCC exon 12
M154r e11 (3393-73) GGAACATCCCGGGATATCATC exon 10
M155s e12 (3556-76) TGCAAATTGACTGCAGTCCTC exon 13
rM156r e12 (3576-56) GAGGACTGCAGTCAATTTGCA exon 11
M157s e13 (3618-42) CAGCCTTCAGACAGTTCTAATTAAC exon 14
M158r e13 (3642-18) GTTAATTAGAACTGTCTGAAGGCT exon 12
M159s e14 (3727-47) CCTGATTTCTTCCTAAGGATC exon 15
M160r e14 (3747-27) GATCCTTAGGAAGAAATCAGG exon 13
M162r e15 (3870-50) ATGGTAGCACAGCCATTCTGC exon 14
M163r e16 (3996-76) CACCGTCTTCAGCAGTTCCAT exon 15
tert e16-M316-r e16 (4041-07) TTAGTCCAGTATAGTTTTGAAATCTTGACAAAGCG chTERT cDNA
TET-tert e4 e4 (2554-78) TET-CAGAAACTCAGCAAGGAAAGCAGAG splice variant 5
tert e6 e6 (2874-55) CCACCTTATTCCATAGACAG splice variant 5
TET-tert e9 e9 (3170-92) TET-GCAGCTTATGCTACGGAGACATG splice variant 10
tert e11 e11 (3361-42) TCACCACAGTCTTCTTGGCA splice variant 10
1 name of the primer with TET labeling indication,
2 localization in the chTERT cDNA sequence AY626231 (NCBI n°)
3 written in the 5’->3’ orientation
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Additional file 1: Comparison of estimates of the levels of splicing
variants 5 and 10 by cDNA cloning and fragment electrophoresis.
Proportions of constitutively spliced chTERT transcript (in blue) and
alternatively spliced variants d10f (in green), 10ec (in orange) and d5f (in
green). The proportions correspond to the peak area obtained by
capillary electrophoresis analysis (CEAA) of PCR targeting variant 10 (A) or
5 (B), performed on cDNA extracted from LMH or MSB1 cells (3
biological analyses) or obtained from cDNA analysis by estimation of the
percentage of all alternative transcripts harboring splicing event 5 or 10
(Figure 1).
Abbreviations
TERT: telomerase reverse transcriptase; TR: telomerase RNA; NMD: nonsense-
mediated decay; PTC: premature termination codon, TRAP: telomere repeat
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